Healthcare Technology Report Names Viveve Regulatory Executive Among Top 25 Women Leaders in Medical Devices

Rhea-AI Summary

Viveve Medical announced that its Senior VP, Suzon Lommel, has been recognized as one of The Top 25 Women Leaders in Medical Devices for 2022 by The Healthcare Technology Report, marking her second consecutive year on this list. Under her leadership, Viveve is advancing its technology to treat stress urinary incontinence (SUI)clinical program for SUI, with top-line results from its ongoing PURSUIT trial expected in late 2022, which could support a new SUI indication in the U.S.

Positive

• Suzon Lommel's recognition as a top leader enhances Viveve's reputation in the medical device industry.
• Progress in the clinical development program for stress urinary incontinence (SUI) could lead to new market opportunities.
• The PURSUIT trial completion may support a new SUI indication and potentially boost revenue.

Negative

• None.

Viveve SVP Suzon Lommel named to list for second consecutive year for efforts to advance innovative technologies to treat stress urinary incontinence in women

ENGLEWOOD, CO / ACCESSWIRE / January 13, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, announced today that Suzon Lommel, the Company's Senior Vice President of Regulatory and Quality Affairs, has been named by The Healthcare Technology Report as one of The Top 25 Women Leaders in Medical Devices of 2022. Ms. Lommel was also named as one of the Top 25 Women Leaders in Medical Devices in 2021.

"Over the past year Viveve has focused on development of our innovative technology for the treatment of stress urinary incontinence or SUI in women. The efforts of Suzon and all the members of our senior team have demonstrated our commitment to leadership and innovation. Suzon has consistently worked to keep us in the lead by expertly anticipating and addressing issues in regulatory and quality affairs, playing an important role in our progress. The entire Viveve organization congratulates Suzon for her outstanding contribution to the medical device industry and this well-deserved recognition," said Scott Durbin, Viveve's Chief Executive Officer.

"In my role at Viveve I have been fortunate to make contributions to advance our unique technology that has the potential to make a profoundly positive difference in the lives of millions of women affected by SUI. I am once again honored to be included with the other women recognized in the Healthcare Technology Report Top 25 Women Leaders in Medical Devices for 2022," said Ms. Lommel. "This honor also once again highlights the outstanding progress of our entire team in working to develop and bring our technology for the treatment of SUI to patients around the world as quickly as possible."

The Healthcare Technology Report annually recognizes top-performing women who have demonstrated a depth of specialized knowledge and leadership to make a positive impact in the medical device field. Showing qualities including adaptability, ingenuity, and patient-centricity, awardees play a central role in advancing the competitiveness of their companies and technologies. They also serve as mentors and role models to promote and support leadership opportunities for women in the healthcare technology sector.

About Viveve

Viveve Medical, Inc. is a medical technology company focused on women's intimate health. Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates Cryogen-cooled Monopolar Radiofrequency technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session. In the United States, the Viveve® System is cleared by the Food and Drug Administration (FDA) for use in general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in more than 50 countries.

Viveve continues to advance its clinical development program in stress urinary incontinence (SUI). Viveve received FDA approval of its IDE application to conduct the multicenter, randomized, double-blinded, sham-controlled PURSUIT trial for improvement of SUI in women in July 2020 and FDA approval of its requested amendments to the IDE protocol in December 2020. Initiation of the trial was reported ain January 2021 and completion of subject enrollment was announced on December 14, 2021. Topline results are anticipated in late 2022. If positive, results from the PURSUIT trial may support a new SUI indication in the U.S.

For more information visit Viveve's website at www.viveve.com.

Safe Harbor Statement

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the impact of the novel coronavirus termed COVID-19 on our clinical development and regulatory review and clearances and on the manufacturing, placements and patient utilization of our Viveve Systems, the performance of management and our employees, our ability to obtain financing, our evaluation of strategic alternatives, our ability to obtain approval or clearance for sale of our medical device for all indications sought, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware, unless required by law.

Viveve is a registered trademark of Viveve, Inc.

Investor Relations contacts:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com

Media contact:
Bill Berry
Berry & Company Public Relations
(212) 253-8881
bberry@berrypr.com

SOURCE: Viveve Medical, Inc.

View source version on accesswire.com:
https://www.accesswire.com/683301/Healthcare-Technology-Report-Names-Viveve-Regulatory-Executive-Among-Top-25-Women-Leaders-in-Medical-Devices

FAQ

What recognition did Viveve Medical's Suzon Lommel receive in 2022?

Suzon Lommel was named one of The Top 25 Women Leaders in Medical Devices for 2022 by The Healthcare Technology Report.

What is the focus of Viveve Medical's clinical development program?

Viveve Medical is focused on developing innovative technologies to treat stress urinary incontinence (SUI) in women.

What are the expected results timeline for Viveve's PURSUIT trial?

Topline results from the PURSUIT trial are anticipated in late 2022.

What technology is Viveve Medical developing for SUI?

Viveve Medical is advancing a unique technology using the Viveve System for the treatment of stress urinary incontinence.

How has the PURSUIT trial progressed?

Viveve Medical announced the completion of subject enrollment for the PURSUIT trial on December 14, 2021.